Pediatrics · LP-011
Zinc sulfate Dispersible tablet
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-011Pediatrics
- Generic identity
- Zinc sulfateDispersible tablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-011
- Generic identity
- Zinc sulfate
- Presentation
- Dispersible tablet
- Catalogue strength
- 10 mg; 20 mg
- Catalogue pack
- Blister 10 x 10 dispersible tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Ingredient wording: zinc sulfate.
- Dosage form: dispersible tablet.
- Source strength values: 10 mg and 20 mg.
- General proposed pack: blister 10 × 10 dispersible tablets.
Layer 02 · Unresolved product-specific fields
- Strength basis: elemental zinc versus zinc sulfate salt mass/equivalent.
- Exact chemical form/hydration state and quantitative composition.
- Whether tablets are scored and the approved dispersion/administration instructions.
- Approved indication, age range, storage, shelf life, registration and supply status.
Identity note
B01 issue P004 remains open. Preserve the source quantities without silently converting them to elemental zinc.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg — basis unspecified | Dispersible tablet | — | Blister 10 × 10 dispersible tablets | Do not label as 10 mg elemental zinc until the strength basis is controlled. |
| B | 20 mg — basis unspecified | Dispersible tablet | — | Blister 10 × 10 dispersible tablets | Do not label as 20 mg elemental zinc until the strength basis is controlled. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Zinc sulfate is a source of the essential mineral zinc. The quantity of elemental zinc is distinct from the mass of zinc sulfate salt, so a strength statement must make that basis clear. Zinc has roles in nutrition and in selected diarrhoea-care programs. This educational profile does not confirm the elemental-zinc equivalence, clinical indication, or regulatory status of the proposed Luang Pharma syrup or dispersible tablet.
Clinical context and therapeutic role
Assessment of zinc need considers diet, malabsorption, clinical findings and the limitations of laboratory measures. WHO includes zinc supplementation within childhood diarrhoea management alongside rehydration and continued nutrition. That use should follow the current national program and individual assessment. Zinc is not a substitute for oral rehydration, diagnosis of persistent diarrhoea, or emergency management of dehydration. Routine supplementation without a clear reason can create unnecessary exposure.
Selected safety context
Nausea, vomiting and abdominal discomfort can occur. Excessive or prolonged zinc intake can impair copper status and cause other nutritional problems. Zinc can reduce absorption of some antibiotics and other medicines, so a pharmacist should review timing and compatibility. Do not combine several zinc-containing products without checking total intake. Marked dehydration, inability to drink, bloody stools or worsening illness requires clinical assessment rather than relying on supplementation.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
A dispersible tablet is intended to be prepared in the manner specified by its approved instructions. The dispersion volume, permitted liquid and administration method are formulation-specific. A dispersible description does not establish elemental-strength equivalence, compatibility with another medicine or suitability for every child.
Use a clean preparation vessel and follow the supplied directions, including any immediate-use requirement. Do not improvise a mixture with another medicine. Keep unused tablets in their labeled protective packaging and verify storage requirements and expiry from the actual product information.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Controlled formula specifying zinc compound, hydration state and elemental-equivalent basis.
Approved label/leaflet identifying the strength basis and dispersion instructions.
Finished-product specification and score/divisibility evidence if applicable.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| WHO: Zinc supplementation in the management of diarrhoeaArchived source classification: WHO clinical public-health guidance | Source revision recorded: Last updated 9 August 2023; Archived access check: 2026-09-11 | External WHO context; reinforces the need to identify the zinc quantity basis but does not establish LP-011/012 formulation or indication. |
| WHO: Production of zinc tablets and zinc oral solutionsArchived source classification: WHO manufacturing/procurement guideline | Source revision recorded: 1 January 2007; Archived access check: 2026-09-11 | External formulation/procurement context; not evidence that LP-011/012 match a WHO zinc product specification. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-011.
Professional enquiries
Request product-specific evidence for LP-011.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.